We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Chagas Diagnostic Test Detects Antibodies to Trypanosoma cruzi

By LabMedica International staff writers
Posted on 30 Nov 2011
A new Chagas in vitro diagnostic test will be used as an additional, more specific test on human serum or plasma specimens found repeatedly reactive using a licensed screening test.

The Abbott ESA Chagas is the first Food and Drug Administration (FDA; Silver Spring, MD, USA)-approved supplemental test that detects antibodies to Trypanosoma cruzi. It is an in vitro enzyme strip assay (ESA) intended for the qualitative detection of antibodies to T. More...
cruzi in human serum and plasma specimens.

Chagas disease is caused by the parasite T. cruzi, which is transmitted to animals and people by insects through contact with the feces of an infected triatomine (Triatominae) bug. Infection also occurs congenitally, through transfusions of contaminated blood products, or through an organ transplant from an infected donor. If left untreated, Chagas disease develops from an acute to a chronic illness, which could result in constipation, digestive problems, abdomen pain, and abnormal heart rhythms or heart failure, which may result in death. Chagas disease is endemic throughout much of Mexico, Central America, and South America.

The US Centers for Disease Control and Prevention (CDC; Atlanta, GA, USA) reports that as many as 11 million people worldwide are infected with Chagas disease. Chagas disease belongs to a group of neglected tropical diseases (NTD) that disproportionately affects the world's poor and rural populations. In the United States, more than 300,000 individuals are estimated to be infected with Chagas disease

The FDA mandated donor screening in 2007. The American Association of Blood Banks (AABB) Chagas Biovigilance Network reports that nearly 1,500 donors with Chagas disease have been identified in the four years since mandatory donor screening was implemented.

Related Links:
Food and Drug Administration
US Centers for Disease Control and Prevention




Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Aspiration System
VACUSAFE
Hematology Consumables
Bioblood Devices
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers developed three mathematical biomarkers from routine PSA blood tests that may help predict early prostate cancer treatment outcomes and personalize adaptive therapy (Image Credit: Adobe Stock)

Mathematical Biomarkers Use Routine Blood Tests to Guide Adaptive Prostate Cancer Therapy

Personalizing systemic therapy for prostate cancer remains challenging because tumors can evolve under treatment pressure, driving resistance and early relapse. Continuous high-dose regimens may initially... Read more

Molecular Diagnostics

view channel
Image: The duet mosaic family comprises duet +modC mosaic and duet 6-base mosaic, two cfDNA-optimized multiomic sequencing workflows for liquid biopsy and translational research. (Photo courtesy of bimodal)

New Liquid Biopsy Workflow Maximizes Tumor Signals from Limited Blood Samples

Liquid biopsy seeks to detect tumor-derived signals from small blood samples, but circulating cell-free DNA is scarce and heterogeneous, limiting sensitivity. Combining complementary signals such as methylation,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.